Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias, Ian D. Davis, Maria De Santis, Eiji Kikuchi, Xavier García del Muro, Ugo De Giorgi, Marina Mencinger, Kouji Izumi, Stefano Panni, Mahmut Gümüş, Mustafa Özgüroğlu, Arash Rezazadeh Kalebasty, Se Hoon Park, B. Yа. Alekseev, Fabio A. Schutz, Jian-Ri Li, Dingwei Ye, Nicholas J. Vogelzang, Sandrine Bernhard, Darren Tayama, Sanjeev Mariathasan, Almut Mecke, AnnChristine Thåström, Enrique Grande
Topics & Concepts
AtezolizumabMedicineMetastatic Urothelial CarcinomaPlaceboCarboplatinGemcitabineChemotherapyInternal medicineUrologyOncologyCisplatinCancerBladder cancerPembrolizumabUrothelial carcinomaImmunotherapyPathologyAlternative medicineBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis